Development of small molecular compounds targeting cancer stem cells

MedChemComm

Volumn 8, Issue 1, 2017, Pages 73-80

  Park, Jae Hyun ^a   Chung, Suyoun ^b   Matsuo, Yo ^b   Nakamura, Yusuke ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Research and Development Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE; OTS 167; OTS 514; OTS 964; T LYMPHOKINE ACTIVATED KILLER CELL ORIGINATED PROTEIN KINASE; TTK 27F; TUMOR MARKER; TYROSINE THREONINE KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; UPREGULATION;

EID: 85010825666     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c6md00385k     Document Type: Review

References (50)

1. A. Kreso J. E. Dick Evolution of the cancer stem cell model Cell Stem Cell 2014 14 275-291
2. G. J. Yoshida H. Saya Therapeutic strategies targeting cancer stem cells Cancer Sci. 2016 107 5-11
3. G. Ghiaur J. Gerber R. J. Jones Concise review: Cancer stem cells and minimal residual disease Stem Cells 2012 30 89-93
4. N. Y. Frank T. Schatton M. H. Frank The therapeutic promise of the cancer stem cell concept J. Clin. Invest. 2010 120 41-50
5. M. Dean T. Fojo S. Bates Tumour stem cells and drug resistance Nat. Rev. Cancer 2005 5 275-284
6. N. Takebe L. Miele P. J. Harris W. Jeong H. Bando M. Kahn S. X. Yang S. P. Ivy Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update Nat. Rev. Clin. Oncol. 2015 12 445-464
7. K. Kono H. Iinuma Y. Akutsu H. Tanaka N. Hayashi Y. Uchikado T. Noguchi H. Fujii K. Okinaka R. Fukushima H. Matsubara M. Ohira H. Baba S. Natsugoe S. Kitano K. Takeda K. Yoshida T. Tsunoda Y. Nakamura Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens J. Transl. Med. 2012 10 141
8. T. Kidokoro C. Tanikawa Y. Furukawa T. Katagiri Y. Nakamura K. Matsuda CDC20, a potential cancer therapeutic target, is negatively regulated by p53 Oncogene 2008 27 1562-1571
9. J. H. Park M. L. Lin T. Nishidate Y. Nakamura T. Katagiri PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer Cancer Res. 2006 66 9186-9195
10. S. Hayama Y. Daigo T. Kato N. Ishikawa T. Yamabuki M. Miyamoto T. Ito E. Tsuchiya S. Kondo Y. Nakamura Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis Cancer Res. 2006 66 10339-10348
11. M. Taniwaki A. Takano N. Ishikawa W. Yasui K. Inai H. Nishimura E. Tsuchiya N. Kohno Y. Nakamura Y. Daigo Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer Clin. Cancer Res. 2007 13 6624-6631
12. M. L. Lin J. H. Park T. Nishidate Y. Nakamura T. Katagiri Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family Breast Cancer Res. 2007 9 R17
13. A. Shimo T. Nishidate T. Ohta M. Fukuda Y. Nakamura T. Katagiri Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells Cancer Sci. 2007 98 174-181
14. K. Taniuchi H. Nakagawa T. Nakamura H. Eguchi H. Ohigashi O. Ishikawa T. Katagiri Y. Nakamura Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell Cancer Res. 2005 65 105-112
15. D. Hirata T. Yamabuki D. Miki T. Ito E. Tsuchiya M. Fujita M. Hosokawa K. Chayama Y. Nakamura Y. Daigo Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression Clin. Cancer Res. 2009 15 256-266
16. T. Ueki T. Nishidate J. H. Park M. L. Lin A. Shimo K. Hirata Y. Nakamura T. Katagiri Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells Oncogene 2008 27 5672-5683
17. A. Shimo C. Tanikawa T. Nishidate M. L. Lin K. Matsuda J. H. Park T. Ueki T. Ohta K. Hirata M. Fukuda Y. Nakamura T. Katagiri Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis Cancer Sci. 2008 99 62-70
18. C. Fukukawa K. Ueda T. Nishidate T. Katagiri Y. Nakamura Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells Genes, Chromosomes Cancer 2010 49 861-872
19. J. Koinuma H. Akiyama M. Fujita M. Hosokawa E. Tsuchiya S. Kondo Y. Nakamura Y. Daigo Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis Cancer Sci. 2012 103 577-586
20. M. Hosokawa A. Takehara K. Matsuda H. Eguchi H. Ohigashi O. Ishikawa Y. Shinomura K. Imai Y. Nakamura H. Nakagawa Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer Cancer Res. 2007 67 2568-2576
21. I. Shats M. L. Gatza J. T. Chang S. Mori J. Wang J. Rich J. R. Nevins Using a stem cell-based signature to guide therapeutic selection in cancer Cancer Res. 2011 71 1772-1780
22. S. Chung H. Suzuki T. Miyamoto N. Takamatsu A. Tatsuguchi K. Ueda K. Kijima Y. Nakamura Y. Matsuo Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer Oncotarget 2012 3 1629-1640
23. M. Komatsu T. Yoshimaru T. Matsuo K. Kiyotani Y. Miyoshi T. Tanahashi K. Rokutan R. Yamaguchi A. Saito S. Imoto S. Miyano Y. Nakamura M. Sasa M. Shimada T. Katagiri Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis Int. J. Oncol. 2013 42 478-506
24. H. Alachkar M. B. Mutonga K. H. Metzeler N. Fulton G. Malnassy T. Herold K. Spiekermann S. K. Bohlander W. Hiddemann Y. Matsuo W. Stock Y. Nakamura Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia Oncotarget 2014 5 12371-12382
25. H. Inoue T. Kato S. Olugbile K. Tamura S. Chung T. Miyamoto Y. Matsuo R. Salgia Y. Nakamura J. H. Park Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer Oncotarget 2016 7 13621-13633
26. T. Kato H. Inoue S. Imoto Y. Tamada T. Miyamoto Y. Matsuo Y. Nakamura J. H. Park Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells Oncotarget 2016 7 17652-17664
27. L. W. Hebbard J. Maurer A. Miller J. Lesperance J. Hassell R. G. Oshima A. V. Terskikh Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo Cancer Res. 2010 70 8863-8873
28. S. Li Z. Li T. Guo X. F. Xing X. Cheng H. Du X. Z. Wen J. F. Ji Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer Oncotarget 2016 7 6266-6280
29. H. Alachkar M. Mutonga G. Malnassy J. H. Park N. Fulton A. Woods L. Meng J. Kline G. Raca O. Odenike N. Takamatsu T. Miyamoto Y. Matsuo W. Stock Y. Nakamura T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia Oncotarget 2015 6 33410-33425
30. Y. Ikeda J. H. Park T. Miyamoto N. Takamatsu T. Kato A. Iwasa S. Okabe Y. Imai K. Fujiwara Y. Nakamura K. Hasegawa T-LAK cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in ovarian cancer Clin. Cancer Res. 2016 10.1158/1078-0432.CCR-16-0207
31. J. H. Park T. Nishidate Y. Nakamura T. Katagiri Critical roles of T-LAK cell-originated protein kinase in cytokinesis Cancer Sci. 2010 101 403-411
32. K. Cao R. Nakajima H. H. Meyer Y. Zheng The AAA-ATPase Cdc48/p97 regulates spindle disassembly at the end of mitosis Cell 2003 115 355-367
33. Y. Abe T. Takeuchi L. Kagawa-Miki N. Ueda K. Shigemoto M. Yasukawa K. Kito A mitotic kinase TOPK enhances Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis J. Mol. Biol. 2007 370 231-245
34. Y. Matsuo J. H. Park T. Miyamoto S. Yamamoto S. Hisada H. Alachkar Y. Nakamura TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis Sci. Transl. Med. 2014 6 259ra145
35. Y. Matsumura Cancer stromal targeting (CAST) therapy Adv. Drug Delivery Rev. 2012 64 710-719
36. K. Joshi Y. Banasavadi-Siddegowda X. Mo S. H. Kim P. Mao C. Kig D. Nardini R. W. Sobol L. M. Chow H. I. Kornblum R. Waclaw M. Beullens I. Nakano MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells Stem Cells 2013 31 1051-1063
37. B. Stangeland A. A. Mughal Z. Grieg C. J. Sandberg M. Joel S. Nygård T. Meling W. Murrell E. O. Vik Mo I. A. Langmoen Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells Oncotarget 2015 6 26192-26215
38. M. Joel A. A. Mughal Z. Grieg W. Murrell S. Palmero B. Mikkelsen H. B. Fjerdingstad C. J. Sandberg J. Behnan J. C. Glover I. A. Langmoen B. Stangeland Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo Mol. Cancer 2015 14 121
39. C. Dominguez-Brauer K. L. Thu J. M. Mason H. Blaser M. R. Bray T. W. Mak Targeting Mitosis in Cancer: Emerging Strategies Mol. Cell 2015 60 524-536
40. Y. Mizukami K. Kono Y. Daigo A. Takano T. Tsunoda Y. Kawaguchi Y. Nakamura H. Fujii Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma Cancer Sci. 2008 99 1448-1454
41. K. Kono Y. Mizukami Y. Daigo A. Takano K. Masuda K. Yoshida T. Tsunoda Y. Kawaguchi Y. Nakamura H. Fujii Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer Cancer Sci. 2009 100 1502-1509
42. K. Kono H. Iinuma Y. Akutsu H. Tanaka N. Hayashi Y. Uchikado T. Noguchi H. Fujii K. Okinaka R. Fukushima H. Matsubara M. Ohira H. Baba S. Natsugoe S. Kitano K. Takeda K. Yoshida T. Tsunoda Y. Nakamura Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens J. Transl. Med. 2012 10 141
43. D. Huang Q. Gao L. Guo C. Zhang W. Jiang H. Li J. Wang X. Han Y. Shi S. H. Lu Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines Stem Cells Dev. 2009 18 465-473
44. W. Zhou Y. Yang Z. Gu H. Wang J. Xia X. Wu X. Zhan D. Levasseur Y. Zhou S. Janz G. Tricot J. Shi F. Zhan ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma Leukemia 2014 28 1155-1158
45. K. Hu J. H. Law A. Fotovati S. E. Dunn Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells Breast Cancer Res. 2012 14 R22
46. K. Kusakabe N. Ide Y. Daigo T. Itoh T. Yamamoto H. Hashizume K. Nozu H. Yoshida G. Tadano S. Tagashira K. Higashino Y. Okano Y. Sato M. Inoue M. Iguchi T. Kanazawa Y. Ishioka K. Dohi Y. Kido S. Sakamoto S. Ando M. Maeda M. Higaki Y. Baba Y. Nakamura Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity J. Med. Chem. 2015 58 1760-1775
47. Y. Liu Y. Lang N. K. Patel G. Ng R. Laufer S. W. Li L. Edwards B. Forrest P. B. Sampson M. Feher F. Ban D. E. Awrey I. Beletskaya G. Mao R. Hodgson O. Plotnikova W. Qiu N. Y. Chirgadze J. M. Mason X. Wei D. C. Lin Y. Che R. Kiarash B. Madeira G. C. Fletcher T. W. Mak M. R. Bray H. W. Pauls The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents J. Med. Chem. 2015 58 3366-3392
48. D. R. Pattabiraman R. A. Weinberg Tackling the cancer stem cells-what challenges do they pose? Nat. Rev. Drug Discovery 2014 13 497-512
49. S. Chung K. Kijima A. Kudo Y. Fujisawa Y. Harada A. Taira N. Takamatsu T. Miyamoto Y. Matsuo Y. Nakamura Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor Oncotarget 2016 7 18171-18182
50. C. A. Lipinski F. Lombardo B. W. Dominy P. J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001 46 3-26